drugset / Trial / NCT00246259
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or hallucinations).
Timeline
- Start
- 2004-10
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 6 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 25 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 37.5 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 50 mg | Intramuscular |
| Comparator | Olanzapine | Small molecule | 20 mg | Oral |
| Comparator | Quetiapine | Small molecule | 800 mg | Oral |